Corporate Presentation March 2024 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successfull ...

Core Insights - The biotech industry, particularly in obesity treatment, is experiencing a significant opportunity with Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, which has shown promising results in clinical trials [3][4][11] - Viking's VK2735 has demonstrated a 14.7% weight loss at 13 weeks with a tolerability profile that matches placebo, setting it apart from competitors like Wegovy and Zepbound, which have higher discontinuation rates [3][4][5][11] - The obesity drug market is projected to reach $200 billion by 2030, and Viking's oral formulation could potentially expand the market by attracting patients who avoid current treatments due to side effects [5][6][21] Company Overview - Viking Therapeutics is developing VK2735, which has shown a 13% discontinuation rate, comparable to placebo, indicating a strong safety profile [4][6] - The company has secured a $150 million manufacturing deal with CordenPharma, ensuring capacity for 100 million autoinjectors and 1 billion tablets annually, which alleviates manufacturing concerns common in small-cap biotechs [18][19] Market Dynamics - Viking's stock has seen a significant decline of 64% from its 52-week high, reflecting broader market challenges rather than company-specific issues [9][10] - Institutional investors are showing confidence in Viking, with significant bullish positions being accumulated, contrasting with rising short interest among retail investors [13][16] Investment Opportunity - The upcoming phase 2 oral data release is anticipated to present an asymmetric investment opportunity, with potential for the oral formulation to achieve efficacy similar to injectables [20][21] - Current market valuation of Viking at $3 billion is significantly lower than the value created by successful GLP-1 drugs, suggesting a potential for revaluation if VK2735's oral formulation proves effective [21][24] - The market is currently pricing Viking as a high-risk investment, but the data suggests a more favorable outlook, with a reasonable probability of success for VK2735 being much higher than the market's implied odds [23][24][25]

Group 1: CRISPR Therapeutics - CRISPR Therapeutics has developed Casgevy, the first gene-editing medicine approved using the CRISPR technique, but the stock has been on a downward trend since 2021 due to clinical progress, complexity of therapy administration, and unprofitability [3][4] - The company is targeting challenging areas such as type 1 diabetes and hard-to-treat cancers, with expected data readouts for ongoing clinical trials as early as this year, which could positively impact stock performance [5] - Casgevy has significant financial implications, with a treatment cost of $2.2 million in the U.S. and an estimated 60,000 patients in target geographies, indicating blockbuster potential [9] Group 2: Viking Therapeutics - Viking Therapeutics gained attention after strong phase 2 results for VK2735, an investigational weight management therapy, but has seen stock performance decline as investors took profits [10] - The anti-obesity therapy market is rapidly growing, and Viking's VK2735 has shown promising mid-stage data, with an oral formulation currently in Phase 2 studies [11] - Viking Therapeutics has a robust pipeline, including VK2809 for metabolic dysfunction-associated steatohepatitis entering phase 3 studies and VK0214 for X-linked adrenoleukodystrophy, which has received orphan drug designation [12][13]

Core Insights - Growth stocks are experiencing significant volatility in 2025 due to geopolitical issues, high interest rates, AI developments, and valuation concerns [1] - Despite the focus on the "Magnificent Seven," there are transformative companies reaching key inflection points that present compelling investment opportunities [1] Company Summaries - **Oscar Health (OSCR)**: Achieved 42% revenue growth to $3 billion in Q1 2025, with membership exceeding 2 million and net income rising to $275 million from $177 million year over year [3][4] - **Equinix (EQIX)**: Operates 260 data centers globally, but stock dropped 16% due to lower-than-expected growth guidance of 5% to 9% annual adjusted funds from operations through 2029 [5][6] - **Viking Therapeutics (VKTX)**: Developing a potential obesity drug VK2735, which showed up to 14.7% weight loss in phase 2 trials; the obesity drug market is projected to reach $130 billion by 2030 [7][8] - **BigBear.ai (BBAI)**: Provides AI-powered analytics with a revenue growth of 2% year over year to $158 million in 2024; trading at 10.6 times trailing sales, offering exposure to practical AI applications [9][10] - **Rocket Lab (RKLB)**: Posted 32% revenue growth to $123 million in Q1 2025, with a focus on its Neutron rocket debuting in late 2025 and a $1.45 billion federal contract [11][12] - **Archer Aviation (ACHR)**: Progressing through FAA certification for electric vertical takeoff aircraft, targeting commercial operations in Abu Dhabi by Q4 2025, with a total addressable market for urban air mobility potentially reaching $1 trillion by 2040 [13][14] - **Joby Aviation (JOBY)**: In the final phase of FAA certification, plans to carry passengers in Dubai by late 2025 or early 2026, backed by a $500 million investment from Toyota [15][16] - **Navitas Semiconductor (NVTS)**: Focused on gallium nitride power semiconductors, despite a 40% revenue decline to $14 million in Q1 2025, positioned for growth in AI data centers and EVs [17] - **Intuitive Machines (LUNR)**: First commercial company to land on the moon, with Q1 2025 revenue of $62.5 million and a contracted backlog of $272 million [18][19] - **Palantir (PLTR)**: Experiencing explosive adoption of its AI Platform, with U.S. commercial revenue surging 71% and government revenue stable at $373 million quarterly [20][21] Market Trends - These companies are targeting massive markets, achieving operational inflection points, and trading at reasonable valuations relative to their potential [22] - The focus on these growth stocks may provide compelling risk-reward opportunities for investors looking beyond the more prominent tech names [23]

Shares in biopharmaceutical company Viking Therapeutics (VKTX 5.35%) were up by 6.3% at 12:30 a.m. ET today. The move likely stems from the market digesting the previous day's news that Viking had initiated a phase 3 trial of its most promising program in its pipeline, namely VK2375, a treatment for metabolic disorders, including obesity.Why VK2375 is exciting investorsThere are probably two key reasons why the market likes the initiation of a phase 3 trial:VK2375 is a dual GLP-1/GIP receptor agonist simila ...

Viking Therapeutics, Inc. (VKTX) closed at $28.59 in the latest trading session, marking a -1.26% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.38%. On the other hand, the Dow registered a gain of 0.24%, and the technology-centric Nasdaq increased by 0.24%. Prior to today's trading, shares of the company had gained 8.96% outpaced the Medical sector's gain of 4.64% and the S&P 500's gain of 6.6%.The investment community will be paying close attention to the earning ...

Company Overview - Viking Therapeutics (VKTX) is a mid-cap biotech company whose shares have declined by 34% this year, indicating potential company-specific developments or broader market issues affecting its attractiveness [1] - The company is in the clinical stage, meaning it has no products on the market, generates no revenue, and is consistently unprofitable, which typically makes it less appealing to investors during periods of market volatility [2] Product Development - Viking Therapeutics is developing medicines in areas with high unmet needs, particularly in weight management, where the anti-obesity drug market is experiencing significant growth [4] - The leading candidate, VK2735, is a dual GLP-1/GIP agonist, competing in the same class as Eli Lilly's Zepbound, which is currently the market leader [4][5] - VK2735 has shown better results than most mid-stage candidates in weight management, suggesting strong potential despite the competition from larger drugmakers [5] Market Potential - Another mid-stage program, VK2809, has performed well in patients with metabolic dysfunction-associated steatohepatitis (MASH), a disease linked to obesity, which is becoming increasingly prevalent [6] - VK2809 could enter a relatively young market in the coming years, potentially generating significant sales [7] Strategic Partnerships - Viking Therapeutics has signed a multiyear manufacturing agreement with CordenPharma for VK2735, which includes the production of over a billion oral formulations and 200 million autoinjectors and syringes annually [7] - The total payments to CordenPharma will amount to $150 million through 2028, indicating that the company is planning for post-commercial activities for its leading candidate [8] Innovation Commitment - The company is also developing another weight management product in preclinical studies, which is a dual agonist mimicking the action of two gut hormones [9] - Viking Therapeutics' commitment to innovation is notable for a small biotech, although there are risks associated with the potential failure of its advanced programs in phase 3 studies [9]

Viking Therapeutics (VKTX) 2025 Conference June 05, 2025 11:40 AM ET Speaker0 Alright. Welcome, everyone, to Jefferies twenty twenty five Global Healthcare Conference. My name is Roger Song, one of the senior analysts cover SimiCAP Biotech in The US. It is my pleasure to introduce our next printing company, Viking Therapeutics CEO, Brian Lian. So he will do a corporate presentation. And if you have some time for q and a toward the end, we'll do that. Welcome, Lian. Speaker1 Great. Thanks, Roger. And thanks ...

Core Insights - Pfizer has decided to discontinue the development of Danuglipron due to safety concerns and is now looking for business development opportunities to acquire promising product candidates [1] Group 1: Company Actions - Pfizer is actively seeking to acquire new product candidates following the halt of Danuglipron's development [1] Group 2: Analyst Background - The analyst has over 20 years of experience in research and development of novel Cell & Gene Therapies, focusing on assessing the potential of new treatments and their ability to generate shareholder returns [1]

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...